I think we don't know what we don't know with respect to the products, because we have a reactive system. In the postmarket space, in the inspection space, and in the advertising complaint space, it's reactive, so it's based either on doing pilots or on something coming to our attention. That's when we can investigate. We really don't have a system that's proactive. We're definitely missing things.
Again, I don't want to misrepresent these products as being riskier than prescription products. That's not the case. They are low-risk, but they are not no-risk. We know that in certain circumstances they can cause considerable harm because of how the products are used, if they're overused, if they're contaminated, if they're used inappropriately. There definitely is an underestimation of the risks.